Want to see HK:2561 full AI Analyst Report?
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$18.50 - HK$45.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)22.27K
Market Cap
HK$2.20B
Enterprise ValueHK$1.80K
Total Cash (Recent Filing)HK$505.81M
Total Debt (Recent Filing)HK$176.71M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding113,926,865
10 Day Avg. Volume16,070
30 Day Avg. Volume22,266
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.12
Revenue Forecast (FY)HK$67.73M
Bulls Say, Bears Say
Bulls Say
Sharp TTM Revenue ReboundThe sharp TTM revenue rebound indicates materially improved commercial traction and a stronger base for future operating leverage. If this growth is sustained, it could help VISEN spread its fixed cost structure over greater sales and progressively improve its earnings profile.
Moderate Leverage And Sizable Equity BaseModerate leverage and a sizable equity base provide greater financial stability than a highly debt-funded structure. This balance-sheet position supports near-term operating capacity and gives management more flexibility to fund development while commercial traction is being established.
Positive Gross Profit In TTMPositive gross profit shows that VISEN's products generated economic value above direct costs during the TTM period. Although operating expenses remain too high, this gross-profit foundation could support margin expansion if revenue scales and the broader cost base becomes more disciplined.
Bears Say
Very Large Continuing Net LossesThe substantial TTM net loss shows that current revenue is far below the level needed to support the company's operating structure. Persistent losses can consume equity, reduce funding flexibility, and delay the point at which the business can become self-sustaining.
Severe Operating And Free Cash BurnDeeply negative operating and free cash flow indicate that VISEN is consuming substantial cash as it runs the business. Unless revenue scales rapidly or costs decline, this burn rate can increase financing dependence and make continued investment in growth more difficult.
Negative Returns On Shareholder CapitalA roughly negative 31% return on equity signals that the existing capital base is currently producing losses rather than attractive returns. If this persists, shareholder value may erode through continued losses and management will need substantially better profitability to justify further investment.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$18.50 and its highest was HK$45.00 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.20B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
VISEN Pharmaceuticals’s upcoming earnings report date is Apr 01, 2027 which is in 195 days.
How were VISEN Pharmaceuticals’s earnings last quarter?
VISEN Pharmaceuticals released its earnings results on Aug 27, 2026. The company reported -HK$1.108 earnings per share for the quarter.
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
VISEN Pharmaceuticals reported an EPS of -HK$1.108 in its last earnings report. Following the earnings report the stock price went down -0.1%.
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VISEN Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―